Canmab 150 mg Injection
  1. Home
  2. Pharma Products
  3. Biocon
  4. Canmab 150 mg Injection

Canmab 150 mg Injection

Canmab 150 mg Injection contains trastuzumab, a targeted monoclonal antibody used for certain HER2-positive cancers. It is mainly used for HER2-positive breast cancer and metastatic gastric cancer. Trastuzumab targets the HER2 protein and helps slow the growth of cancer cells.

BUY NOW

Category

Canmab 150 mg Injection is administered by intravenous infusion under qualified medical supervision. Trastuzumab binds to HER2 receptors on cancer cells and interferes with signaling involved in cancer-cell growth and survival. The 150 mg presentation is a lyophilized powder that requires reconstitution before intravenous infusion. Treatment requires monitoring for infusion-related reactions and cardiac function during therapy.

Technical Specification

Specification Details
Active Ingredient Trastuzumab
Strength 150 mg
Dosage Form Lyophilized Powder for Injection
Route of Administration Intravenous Infusion
Pack Size 1 Vial
Manufacturer Biocon Ltd

Product Also Known As

Canmab 150 mg Injection, Trastuzumab 150 mg Injection, Canmab Trastuzumab Injection, Trastuzumab HER2 Therapy, HER2 Positive Cancer Injection, Breast Cancer Targeted Therapy Injection